Maastricht PhD in Spatial Multi-Omics and Single-Cell Analysis of Human Disease

Maastricht PhD in Spatial Multi-Omics and Single-Cell Analysis of Human Disease

Quick Decision

A strong methods-oriented opportunity, provided the first-year scope is defined. This paid doctorate asks how molecular maps of tissue can be connected to individual cells and their local environments. M4i's imaging and instrumentation environment and the supervisor's directly relevant multimodal studies are its main strengths. The main uncertainty is breadth: the advertisement names several diseases and platforms without defining a cohort or the balance between laboratory, instrumentation and computational work. Ask which biological question and dataset will anchor the first year.

The employer vacancy description and closing field both list 8 November 2026; an earlier project record lists 9 November. No closing time is stated. Confirm the applicable deadline and that the portal is still accepting applications before submitting. The anticipated start is January 2027. The initial contract is 12 months, with the prospect of a further three years. Official vacancy.

Research Problem and Doctoral Work

Tissue-level molecular signals can obscure which cells produced them, while isolated-cell measurements can lose spatial context. The doctoral work connects these scales by generating and integrating patient-derived data and developing methods that link spatial molecular profiles to individual cells. The advertised approaches include MALDI mass-spectrometry imaging, laser microdissection, spatial transcriptomics, single-cell omics, digital pathology and AI-driven analysis. Cancer, inflammation, metabolic disease and environmental health are possible application areas, not four assigned thesis projects or confirmation of a fixed cancer cohort. A central scientific challenge is whether modalities truly describe the same biological objects. Adjacent tissue sections can sample different cells, while measuring several modalities on one section can change what is recovered. A 2025 Cuypers-group study shows both sides: improved spatial correspondence on one section, alongside around 30% fewer transcripts per cell after the MSI measurement, while cell recovery and cell-type assignment were preserved. This is a measurement trade-off, not a general claim that every added modality is harmless. Same-section study. Analyst-proposed questions include what is genuinely paired, how technical and patient-level variation are distinguished, whether a model works beyond the discovery cohort, and whether an apparent molecular marker has independent support. These are interview topics rather than a laboratory protocol or prescribed model. Potential doctoral outputs include a validated integration method, reusable analysis and a disease-focused study, but neither a diagnostic product nor clinical efficacy is promised. The field's scientific programme already foregrounds sampling bias, resolution/time/sensitivity/data-size trade-offs, data quality and multimodal integration. This supports a thesis built around reliable measurement and validation, rather than merely accumulating platforms. IMSIS 2025 programme.

School, Programme and Field Context

The employer and doctoral university are Maastricht University. The scientific home is the Imaging Mass Spectrometry division of the Maastricht MultiModal Molecular Imaging Institute, within FHML and its clinical MUMC+ environment. The exact graduate school and full supervisory/promotor team are not named. The university's international environment is real context, but it does not replace the specific supervision and cohort checks. Institutional setting, FHML doctorate. Subject strength is supported by complementary imaging instrumentation, image-processing/data resources and relevant recent publications. The facility page lists several MS platforms, sample-handling support, storage and cluster resources; some descriptions are historical, so current access, staffing and queues must be checked. Availability at institute level does not establish an unlimited individual allocation. M4i facilities. The official ranking table displays numerical positions without clearly identifying their editions. An undated figure cannot establish a 2026 rank, and an overall university score does not measure spatial-imaging expertise. Ranking context and limitations. FHML requires a Personal Research Plan and Training & Supervision Plan within the first 12 weeks, annual updates, and a tailored training path. Faculty guidance expects 20–35 ECTS and says internal doctoral candidates may devote up to about 10% of appointed time to teaching; the exact post's allocation should be agreed. University-wide requirements include research ethics/integrity, open science and science communication. Foreign-master's validity checks and faculty admission are separate administrative responsibilities. Research/training plans, Doctoral regulations.

Supervisor, Lab and Recent Papers

Eva Cuypers became associate professor and group leader in 2023. Her Peri-Operative Diagnostics group focuses on translating molecular imaging towards clinical needs, with clinicians as end users. The institutional profile confirms her M4i/FHML role and recent output. This supports analytical and translational supervision; the vacancy still needs concrete arrangements for computational, pathology and sample-governance expertise. Group, Research profile.

• One section, two worlds, Scientific Reports 15:42660, 2025, Hendriks and colleagues with Cuypers, combines MALDI-MSI with spatial transcriptomics on a single tissue section. Its contribution is closer correspondence between molecular layers, with a quantified readout trade-off. It directly informs the proposed integration theme without proving general clinical utility. Paper.
• Molecular Profiling of Glioblastoma Patient-Derived Single Cells, Analytical Chemistry, 2025, Krestensen and colleagues with Heeren and Cuypers, links untargeted lipid information and targeted protein annotations in isolated cells and demonstrates cell-type classification. It is a useful proof of concept for multimodal interpretation, not an independently validated patient diagnostic. The indexed abstract supports this summary but does not establish independent clinical validation. Indexed abstract.
• 'On the Spot' Digital Pathology of Breast Cancer Based on Single-Cell Mass Spectrometry Imaging, Analytical Chemistry 94(16):6180–6190, 2022 (online 12 April; issue 26 April; DOI 10.1021/acs.analchem.1c05238), Cuypers first author with Claes, Biemans, Lieuwes, Glunde, Dubois and Heeren, is a third original research study within the last five years. Its published abstract describes molecular classification across 14 breast-cancer cell lines and a tissue-context demonstration. Reported cross-validation up to 97% is an internal study result, not independent patient-level diagnostic accuracy. It supports the supervisor's cell-to-tissue interpretation expertise; the selected disease and model are not assigned to this new doctorate. The indexed abstract and bibliographic record support this summary but do not establish the full methodological detail. Published original-research abstract.
• MSI in spatial biology of pancreatic cancer, Analyst 151(7):1861–1880, 2026, Nieste, Olde Damink, Heeren, Cuypers and Bouwense, reviews tumour heterogeneity, biomarker studies and clinical-translation limitations. It contributes synthesis rather than a new experimental cohort. Pancreatic cancer in that review is not confirmation of this PhD's disease. Published review abstract. The three original studies are distinct from the review: two 2025 papers and the 2022 Cuypers-first-author study establish the recent primary-research evidence; the 2026 review supplies field synthesis and does not count as a third primary paper. The university's 2022 NGID announcement also places Cuypers in a national skin-disease collaboration involving clinicians, imaging and data integration. It demonstrates network context, not the funding source or assigned cohort for this new vacancy. Collaboration background.

Funding, International Eligibility and Maastricht Costs

The 38-hour full-time salary is €3,204–4,051 gross/month, with 8% holiday allowance and 8.3% year-end bonus. The 12-month initial contract has a three-year extension prospect, rather than an unconditional four-year appointment. Benefits include 29 vacation days, four specified additional days, optional accrual of up to 12 compensation days, ABP pension, flexible working and home-office arrangements. The extra compensation days should not be presented as automatic leave. The university's paid-PhD guidance explicitly describes salary with no tuition fees. This distinguishes the position from unrelated external or fee-paying PhD programmes; their fees must not be imported here. Ask about any exceptional personal costs and agreed training/conference budgets, not an assumed international master's fee. Paid-PhD route. The vacancy description does not state a Chinese-nationality restriction or require a CSC award. A relevant MSc, approved admission and legal employment/residence remain required. IND's researcher route is conditional on sponsorship, degree/project/contract and income requirements; the university must identify the appropriate route. C1 English is an explicit vacancy requirement, although acceptable proof and exemptions are not specified. IND guidance. The university's Version 2026 non-EU student cost sheet totals €1,250/month, or €15,000/year, including €650 housing and other illustrative expenses. It is a student expense reference, not a housing offer, and its student-residence financial threshold must not be applied as the employed researcher's visa rule. An analyst buffer scenario of €1,500–1,800/month, or €18,000–21,600/year, allows €250–550 above that reference for differing rents and spending. That scenario is an assumption, not a measured employee average. Compare a real lease and HR net-pay estimate; deposits and relocation are additional. 2026 cost sheet.

Requirements, Advantages and Preparation

Required: a master's in biomedical science, medicine, (bio)chemistry, analytical science/technology or a related subject; English C1 or above; basic hands-on molecular-analysis laboratory experience; practical research/data-analysis ability; and clear scientific communication. Advantages: imaging, understanding mass spectra, ion beams/optics, laser imaging, data science including R/Python, and biological-sample handling experience. The advertisement does not demand that every candidate already master every platform. Suggested preparation: present one clear measurement or data-integration example, explain technical uncertainty and validation, and distinguish what was observed from what a model inferred. No first-author publication quota or specific instrument certification is established.

Career Relevance

The skills developed could support analytical or molecular-imaging R&D, core-facility and application science, computational biomedical research, or instrument and software work. ASMS provides a professional community and career mentoring; this is evidence of career infrastructure, not a quantified hiring boom or this lab's placement rate. A clinical diagnosis or treatment qualification does not follow automatically from the project. Professional community, Career mentoring.

Next Actions and Questions

Before applying: submit CV, motivation letter, tertiary-degree copies and at least two reference contacts via the university portal by 8 November. Ask e.cuypers@maastrichtuniversity.nl about the initial cohort/disease, C1 proof and foreign-degree process. Internal candidates have priority at equal qualifications, not an exclusive route. At interview: establish the wet-lab/instrument/computational split, available paired samples, permission and pathology support, primary validation question, co-supervisors and first-year milestones. Ask how instrument queues and engineering help are budgeted rather than assume everything on the facility list is immediately available. Before accepting: obtain renewal criteria, personal net-pay/relocation arrangements, admission and residence handling, agreed research/training budget and the full supervisory plan. The opportunity's breadth becomes an advantage only when narrowed into a feasible four-year research and training plan.

Evidence and Sources

The employer vacancy description and closing field list 8 November 2026; an earlier project record lists 9 November, and no exact closing time is stated. Confirm that the application portal is still open and verify the deadline before submission. The 2026 cost and permit figures above apply only to their stated year. Paper summaries distinguish primary studies from a review and identify where a claim rests on an abstract or bibliographic record.

• Maastricht vacancy 3853: spatial multi-omics and single-cell human disease
• Eva Cuypers Peri-Operative Diagnostics group
• Eva Cuypers institutional research profile
• One section, two worlds: same-section MALDI-MSI and spatial transcriptomics
• Molecular Profiling of Glioblastoma Patient-Derived Single Cells
• MSI in spatial biology of pancreatic cancer
• M4i molecular imaging infrastructure
• Maastricht paid PhD route
• Maastricht doctoral regulations and foreign-degree validation
• FHML Personal Research Plan and Training and Supervision Plan
• FHML/MUMC doctoral organisation
• Maastricht official rankings and limitations
• Maastricht 2026 non-EU student cost breakdown
• IND researcher residence permit 2026
• ASMS career mentoring
• ASMS professional community
• NGID national clinical-imaging collaboration 2022
• IMSIS III scientific programme 2025
• Maastricht international academic environment
• Cuypers et al. 2022: 'On the Spot' Digital Pathology of Breast Cancer Based on Single-Cell Mass Spectrometry Imaging

Bibliographic record and authors

• One section, two worlds: Tim F. E. Hendriks; Gert B. Eijkel; Theodoros Visvikis; Benjamin Balluff; Ron M. A. Heeren; Eva Cuypers. Scientific Reports 15:42660, 2025.
• Molecular Profiling of Glioblastoma Patient-Derived Single Cells: K. K. Krestensen; T. F. E. Hendriks; A. Grgic; M. Derweduwe; F. DeSmet; R. M. A. Heeren; E. Cuypers. Analytical Chemistry, 2025.
• MSI in spatial biology of pancreatic cancer: Nadine Nieste; Steven W. M. OldeDamink; Ron M. A. Heeren; Eva Cuypers; Stefan A. W. Bouwense. Analyst 151(7), 1861–1880, 2026; review.
• 'On the Spot' Digital Pathology of Breast Cancer Based on Single-Cell Mass Spectrometry Imaging: Eva Cuypers; Britt S R Claes; Rianne Biemans; Natasja G Lieuwes; Kristine Glunde; Ludwig Dubois; Ron M A Heeren. Analytical Chemistry 94(16), 6180–6190, 2022.